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Biopharmaceutical approaches have identified new biologic-based therapies that target key cells and mediators that drive inflammatory responses in the asthmatic lung. This review based on English-language original articles in Pub Med or MedLine published in the last 5 years will update the current status, therapeutic potential and potential problems of recent drug developments in asthma therapy. 

It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics including IL-4, IL-5 and IL-13. However, clinical trials with these biologics in patients with asthma were for the most part disappointing even though they proved to be highly effective in animal models of asthma.
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Eosinophils play an important protective role in the immune response to parasitic infections and, detrimentally, in inflammatory conditions affecting the upper and lower airways, skin and gastrointestinal tract. Eosinophils are not normally present in healthy lungs but their accumulation is a well defined feature of the inflammatory processes in the lungs of patients with allergic asthma where release of their arsenal of pro-inflammatory mediators makes a major contribution to asthma pathogenesis. It has long been known that interleukin (IL)-5 is crucial to the development and release of eosinophils from the bone marrow, their enhanced adhesion to endothelial cells lining the post-capillary venules and their persistence, activation and secretion in the tissues. IL-5 was therefore selected as a potential target to prevent or blunt eosinophil-mediated inflammation in patients with asthma, leading to the development of humanized anti-IL-5 mAb, such as mepolizumab, reslizumab and benralizumab [​[7]​]. Early clinical trials with mepolizumab in patients with mild to severe asthma reported significant reductions in blood and sputum eosinophil numbers but clinical outcomes were disappointing, most likely because subjects were recruited on the basis of clinical and physiological characteristics rather than the presence of eosinophilic airway inflammation [​[8]​]. Asthma management strategies aimed at the control of eosinophilic airway inflammation in addition to clinical manifestations of the condition are associated with a reduction in the frequency of exacerbations [​[9]​]. Importantly therefore, two studies demonstrated that mepolizumab treatment of asthmatics not only reduced eosinophil numbers in the blood and sputum but also resulted in a significant reduction in asthma exacerbations. Both studies were randomized, double-blind, placebo-controlled, parallel-group studies that investigated the effects of monthly infusions of 750 mg mepolizumab or placebo. The first study [​[10]​] used patients with a sputum eosinophilia whose asthma symptoms were refractory to high-dose corticosteroids and who had greater than two exacerbations requiring oral corticosteroids during the previous 12 months. The primary end point was the number of severe exacerbations per patient; secondary outcomes included asthma symptoms, health-related quality of life (HRQoL) measured with the Asthma Quality of Life Questionnaire (AQLQ), lung function, AHR and blood and sputum, eosinophil count. Compared with placebo (32 patients), mepolizumab treatment (29 patients) resulted in a significant reduction in blood sputum eosinophil numbers, with fewer severe exacerbations per patient as compared to placebo together with a significant improvement in quality of life. No significant improvements were reported for the other outcome measures and mepolizumab appeared to be well tolerated. The second study [​[11]​] used fewer patients (9 active, 11 placebo). These subjects exhibited persistent sputum eosinophilia despite requiring oral prednisone for control of asthma symptoms together with a history of exacerbations. In the mepolizumab treated group, one patient had an exacerbation compared with twelve exacerbations in the placebo group. Of those subjects in the placebo group, 9/10 of those analyzed exhibited sputum eosinophilia at the time of exacerbation while in the treatment group mepolizumab significantly reduced sputum and blood eosinophil counts to normal values. Mepolizumab treatment gave a significant and sustained reduction in the oral prednisone dose, a modest improvement in lung function, significant improvement in scores on the Juniper Asthma Control Questionnaire and quality of life indices with no significant side effects reported. These studies in highly selected asthma patient populations demonstrate that mepolizumab attenuates aspects of eosinophil-induced airway inflammation refractive to GC therapy and may therefore potentially interfere with eosinophil-induced airway remodelling in addition to reducing asthma exacerbations. Mepolizumab may also prove useful in other settings such as GC resistant asthma or asthma in smokers with a sputum eosinophilia. However, as mepolizumab had no effect on AHR it is unlikely to be an effective mono therapy for asthma and it is only likely to be effective in tightly defined patient populations who exhibit eosinophil-induced airway inflammation. In addition, a recent open-label trial of seven patients [​[12]​] and a case report of one patient [​[13]​] suggested that mepolizumab may also be effective in the treatment of the eosinophilic disease Churg-Strauss syndrome, in which IL-5 plays a pivotal role.  

Ception Therapeutics Inc (presumed to be under license from Schering-Plough Corp and UCB Celltech) are developing the humanized anti-IL-5 mAb reslizumab. One recent randomized, placebo-controlled trial evaluated intravenous infusions of reslizumab (3.0 mg/kg) or placebo at weeks 0, 4, 8 and 12 in 106 patients with poorly controlled asthma who were taking high-dose inhaled GCs and exhibited a sputum eosinophilia greater than 3%.  When all patients were included for analysis, there was a non-significant trend toward improvement in asthma control associated with a significant improvement in lung function as assessed by the Asthma Control Questionnaire score together with a significant decrease in sputum eosinophilia. In those patients with concomitant nasal polyposis, reslizumab treatment was associated with a significant improvement in asthma symptom control at baseline compared with week 15. There was a non-significant reduction in asthma exacerbations in the reslizumab group while the adverse-event profile for reslizumab and placebo were similar [​[14]​]. Other data from limited pilot trials suggested that reslizumab was a potentially efficacious and well-tolerated treatment for eosinophilic esophagitis, hypereosinophilic syndrome and eosinophilic nasal polyposis [​[15]​]. 

Benralizumab is a novel humanised afucosylated IgG1 mAb indicated for the potential treatment of asthma and COPD that binds to a distinct epitope within the extracellular domain of recombinant human IL-5R.  At the time of publication, benralizumab was undergoing phase II clinical trials in both the specified indications (ClinicalTrials.gov identifiers: NCT01238861 and NCT01227278). Afucosylation is associated with enhanced antibody-dependent cell cytotoxicity and benralizumab was found to induce apoptosis in eosinophils and basophils [​[16]​]. Other anti-IL-5 mAb act by neutralising the effects of IL-5 whereas benralizumab targets the effector cells, mainly eosinophils and basophils, many of whose functions are driven by IL-5. Tissue eosinophils resident in bronchial biopsies of patients with mild atopic asthma exhibited intense immune positivity for benralizumab in contrast to resident mast cells, which were negative [16]. These findings indicate that benralizumab binds human lung tissue-resident eosinophils expressing IL-5Ralpha and could delete these cells, thereby acting as a potential asthma therapeutic. Indeed a phase-1 study in subjects with mild asthma demonstrated that intravenous benralizumab (0.3-3.0 mg/kg) rapidly induced near total depletion of peripheral blood eosinophils while exhibiting an adequate safety profile and dose-proportional pharmacokinetics [​[17]​]. 

IL-4 and IL-13 
Eosinophil involvement as a major pro-inflammatory effector cell in asthma is well-established [​[18]​] with T-helper-2 (TH-2) cells that express IL-4, IL-5 and IL-13 representing essential and central co-ordinators of asthmatic inflammation [​[19]​]. Both IL-4 and IL-13 are important in eosinophil accumulation and are key factors in IgE synthesis by B cells [​[20]​]. There is also evidence that in asthma IL-13 may act directly on airway smooth muscle cell contractility [​[21]​,​[22]​, ​[23]​]; this together with direct effects by IL-13 on epithelial cells and mucus production [​[24]​] may contribute to AHR and airway narrowing. The genes encoding IL-4 and IL-13 are located on the cytokine cluster on chromosome 5q31; both cytokines share some structural similarities. Each exerts their actions through the IL-4R/IL-13R1 receptor complex which then activates the transcription factor STAT-6 [​[25]​]. They therefore have multiple overlapping functions although IL-4 has independent effects via the IL-4R receptor. 

Receptors for IL-13 are expressed by a multitude of cell types important in the pathogenesis of asthma including eosinophils, mast cells together with structural airway epithelial cells, fibroblasts and smooth muscle cells. In asthma, the most important cellular sources of IL-13 are T cells, mast cells and eosinophils. Increased levels of IL-13 have been reported in the sputum and bronchial biopsies from patients with asthma which correlated with increased eosinophil numbers [​[26]​, ​[27]​]. Importantly, mast cells expressing IL-13 are present within the airway smooth muscle in asthmatic subjects suggesting a pivotal role for IL-13 in interactions between these cell types [​[28]​]. IL-13 may also have direct effects on airway smooth muscle function by enhancing the contraction effect of acetylcholine [​[29]​]. It is now widely appreciated that the asthmatic airway epithelium is intrinsically abnormal and critically contributes to the airway inflammatory response [​[30]​]. An important aspect of IL-13 therefore is the effect it has on the functions of airway epithelial cells including induction of a hyper-secretory state [​[31]​] and reduced barrier function through down-regulation of proteins associated with maintaining epithelial tight junctions [​[32]​]. IL-13 is a potent promoter of epithelial cell TGF production; that in turn activates myofibroblasts and is also involved in ECM deposition leading to sub-epithelial membrane thickening; both thought to contribute to airway remodelling [​[33]​, ​[34]​].  IL-13 therefore appears to represent a potentially effective target for asthma therapy [​[35]​]. 

The anti-IL-13 mAb lebrikizumab (Genentech/Chugai Pharmaceutical) has recently been demonstrated to significantly improve lung function in patients with inadequately controlled asthma, but only in a subgroup defined on the basis of high serum levels of periostin [​[36]​]. The latter is a cellular matrix protein that is released by airway epithelial cells stimulated with IL-13. Periostin exhibits effects on epithelial cells and fibroblasts that may contribute to airway remodelling in asthma [​[37]​, ​[38]​].





Tumour necrosis factor (TNF)-α is an important cytokine in innate immune responses that has been implicated in several chronic inflammatory diseases including rheumatoid arthritis and Crohn’s disease with anti-TNFα therapy proving useful in these conditions. It is produced principally by macrophages while other pro-inflammatory cells including monocytes, dendritic cells, B lymphocytes, T cells, neutrophils, mast cells and eosinophils, together with the structural cells fibroblasts, epithelial cells and smooth muscle cells represent significant sources. TNF- has pro-inflammatory effects on eosinophils, neutrophils, T cells, epithelial cells and endothelial cells and may play a key role in amplifying airway inflammation through activation of transcription factors such as NF-B and AP-1. TNF- is expressed in biopsies and lavage fluid from asthmatic airways, particularly in patients with severe asthma compared with those with well-controlled disease. TNF- is thought to contribute to AHR, airway remodelling and GC resistance in asthma and therefore represents a potential target for therapy [7]. Humanized murine anti-TNF mAb (infliximab) and soluble TNF receptor linked to human IgG1 (etanercept) have been developed and preliminary clinical studies in asthma did show significant improvements in lung function, airway hypereactivity and exacerbation rate, particularly in patients with severe asthma refractory to GC treatment [​[42]​]. However, a more recent clinical trial with the anti-TNF biologic golimumab in patients with severe uncontrolled persistent asthma reported negative clinical findings.  Importantly, this study was terminated early due to unacceptable adverse events including frequent serious infections, eight malignancies and one death in the active-treatment group compared with the placebo group [​[43]​]. Overall it appears that TNF- inhibitors are effective in a sub-group of patients with asthma and that identification of the correct patient population may improve clinical outcomes [​[44]​]. However, the unfavorable risk/benefit ratio exhibited by golimumab does cast doubt on the future of anti-TNF therapy in severe asthma. 

3.0 Conclusion
The development of novel asthma anti-inflammatory therapy based on targeting cytokines has proven to be for the most part disappointing; in particular results from animal-based studies have been very misleading. The majority of biologics have proven inadequate in the clinical setting in asthma even though they were highly effective in animal models of asthma. This issue has been emphasized recently by Holgate who points out that at the time of publication of his review articles, out of around 3,000 peer-reviewed publications implicating IL-13 as a central mediator in asthma, only four relate to direct evidence in human asthma [​[45]​]. Two of the latter studies demonstrated that elevated levels of IL-13 were present in the sputum of around half of asthmatic patients tested with no significant association with disease severity [26, 27]. It is not surprising therefore that anti-IL-13 therapy proved to be disappointing in asthma therapy given that only half of the patients recruited to a given clinical trial have any likelihood of responding to this biologic. Indeed the development of discriminatory biomarkers and genetic profiling may identify patients with particular sub-phenotypes of asthma. This point is illustrated by the recent studies that suggest that both mepolizumab and lebrikizumab therapy have beneficial effects in carefully selected patient populations.  
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